Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial.
The role of ciprofloxacin and trimethoprim-sulfamethoxazole (TMP-SMZ) was evaluated in empiric treatment of uncomplicated Salmonella enteritis in a comparative, double-blind trial. Patients were randomized to receive ciprofloxacin (500 mg), TMP-SMZ (160/800 mg), or placebo orally twice daily for 5 days. There were 65 evaluatable patients with acute, uncomplicated, culture-confirmed Salmonella enteritis. Duration of diarrhea, abdominal pain, or vomiting and time to defervescence were not significantly different for patients treated with ciprofloxacin, TMP-SMZ, or placebo; there also were no significant differences with respect to full resolution of symptoms for ciprofloxacin versus placebo (point estimate, 0.2 days; 95% confidence interval [CI], -0.5 to 0.9 days) or for TMP-SMZ versus placebo (point estimate, 0.2 days; 95% CI, -1.0 to 0.6 days). The rate of clearance of salmonellae from stools was not significantly different among the groups.
Sánchez
C
C
Dept. of Medicine, Hospital de Mútua de Terrassa, Barcelona, Spain.
García-Restoy
E
E
Garau
J
J
Bella
F
F
Freixas
N
N
Simó
M
M
Lite
J
J
Sánchez
P
P
Espejo
E
E
Cobo
E
E
D000208:Acute Disease; D000328:Adult; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D004751:Enteritis / Q000188:drug therapy*; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012480:Salmonella Infections / Q000188:drug therapy*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D004338:Drug Combinations; D002939:Ciprofloxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination